Meeting Report: 2023 Muscular Dystrophy Association Summit on ‘Safety and Challenges in Gene Therapy of Neuromuscular Diseases’
Angela Lek(Muscular Dystrophy Association), Carsten G. Bönnemann(National Institute of Neurological Disorders and Stroke), Jordan K. Abbott(Columbia University), Evrim Atas(Muscular Dystrophy Association), Brian L. Lin(Muscular Dystrophy Association), Barry J. Byrne(University of Florida), Sharon Hesterlee(Muscular Dystrophy Association)
Cited by 7
Related Papers
Improving genetic diagnosis in Mendelian disease with transcriptome sequencing
|Science Translational Medicine|2017|809
Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne’s Muscular Dystrophy
|New England Journal of Medicine|2023|302
Targeted Disruption of the Acid α-Glucosidase Gene in Mice Causes an Illness with Critical Features of Both Infantile and Adult Human Glycogen Storage Disease Type II
|Journal of Biological Chemistry|1998|298
Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease
|Genetics in Medicine|2009|292
Sustained alpha‐sarcoglycan gene expression after gene transfer in limb‐girdle muscular dystrophy, type 2D
|Annals of Neurology|2010|243